Categories: Health

EssilorLuxottica to acquire PUcores division dedicated to the development, manufacturing and sale of ophthalmic lens materials

EssilorLuxottica to acquire PUcore’s division dedicated to the development, manufacturing and sale of ophthalmic lens materials 

The acquisition will enhance the Group’s R&D and production capabilities for the manufacturing of innovative high index, thinner and lighter ophthalmic lenses, and ensure long term sustainable sourcing

Paris, France (21 July 2025) – EssilorLuxottica announces today it has signed an agreement with the South Korean company PUcore for the acquisition of all its assets and entities involved in the development, manufacturing and sale of monomers used in the production of high index ophthalmic lenses.

The activities acquired by EssilorLuxottica include a R&D unit, a materials production facility and a sales office in the Republic of Korea. As part of the transaction, the Group will also acquire an intellectual property portfolio in relation to the formulations of products and production processes.

“We are happy to welcome PUcore’s optical division and its talented teams into our Group. In line with our commitment to elevating standards in the research, development and manufacturing of ophthalmic lenses, this addition will allow us to widen our portfolio of patents, technologies and know-how and extend our expertise upstream in the value chain. By continuing to improve the production and formulation of high index monomers, we will raise the bar for the performance and sustainability of the processes and supplies used across the entire ophthalmic industry,” commented Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer at EssilorLuxottica.

The transaction is expected to close by the end of 2025 pending regulatory approvals and other customary closing conditions.

GlobeNews Wire

Recent Posts

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise…

2 weeks ago

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

3 weeks ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

4 weeks ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

4 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

2 months ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

2 months ago